Rankings
▼
Calendar
TNGX Q3 2020 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q3 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
-$11M
Gross Profit
-$24M
215.2% margin
Operating Income
-$27M
237.6% margin
Net Income
-$27M
238.0% margin
EPS (Diluted)
$-0.00
QoQ Revenue Growth
-322.4%
Cash Flow
Operating Cash Flow
$111M
Free Cash Flow
$111M
Stock-Based Comp.
$418,000
Balance Sheet
Total Assets
$168M
Total Liabilities
$6M
Stockholders' Equity
$162M
Cash & Equivalents
$2M
← FY 2020
All Quarters
Q4 2020 →